CDK12 and prostate cancer: Importantly, prostate cancer poses a particular challenge for more naive single measure approaches that produce genomic instability scores, since copy number changes are pervasive (and therefore nonspecific to HRR-deficient genomes) and there are multiple classes of DDR defect associated with genome instability (including CDK12 mutations) which are not associated with disease response to PARP inhibition41.